Feldan Therapeutics is proud to take part, alongside Aramis Biotechnologies, in a collaborative project funded by Médicament Québec. Carried out by Prof. Marc-André Fortin of the CHU de Québec Research Centre – Université Laval, the project aims to accelerate the generation of reliable scientific data in nanomedicine through the development of an advanced analytical service tailored to these products. Ultimately, the service will be available to companies and university research teams working in this field. Overall, Médicament Québec is investing in four industry-academia collaborations. The program is supported by the Ministère de l'Économie, de l'Innovation et de l'Énergie (MEIE).
For Feldan, this initiative reflects an ongoing commitment to draw on the province’s scientific excellence to advance therapies based on intracellular delivery. By combining industry and academic strengths, such partnerships help accelerate the transfer of research into tangible applications for patients and build lasting capabilities within the local life sciences ecosystem. Soultan Al-Halifa, Director R&D – Drug Delivery Technologies, will lead Feldan’s contribution to the project. Feldan thanks Médicament Québec for its support and looks forward to working with Prof. Fortin and his team.
Read the full article here: https://medicamentquebec.ca/index.php/2026/10/19/medicament-quebec-invests-1-2-million-in-four-industry-academia-collaborations-to-accelerate-drug-development-in-quebec/?lang=en